Table 3 Net and incremental benefits from the government use licenses, comparing public health expenditure prior to and after the government use licenses

EFV

1^st line ARV

17,959

(21.3%)

309

97

212

67.0

(50.6%)

NVP

301

156

145

LPV/r

2^nd line ARV

3,421

(4.0%)

8.6

6.9

1.7

2.3

(1.7%)

IDV/r

8.6

9.2

-0.6

Clopidogrel+ASA

2^nd prevention of ischemic events

40,947

(48.7%)

870.6

0.9

869.7

5.7

(4.3%)

ASA only

864.1

0.1

864.0

Letrozole

Breast Cancer Hormone therapy

8,916

(10.6%)

343

2

341

12.0

(9.1%)

Tamoxifen

332

3

329

Docetaxel

Breast Cancer Chemo therapy

5,958

(7.1%)

14.6

1.3

13.3

12.5

(9.5%)

Paclitaxel

11.1

10.3

0.8

Docetaxel

Lung Cancer Chemo therapy

4,855

(5.8%)

5.6

0.8

4.8

25.7

(19.4%)

Pemetrexed

5.6

26.5

-20.9

Erlotinib

Lung Cancer Chemo therapy

256

(0.3%)

0.3

0.6

-0.3

-*

Gifitinib

N/A

N/A

N/A

Imatinib

CML Chemo therapy

1,293

(1.5%)

4.1

-**

4.1

7.2

(5.4%)

GIST Chemo therapy

553

(0.7%)

3.1

-**

3.1

Total

84,158

(100%)

132.4

(100%)